tilvestamab

Tilvestamab is a fully humanized monoclonal antibody that selectively targets and inhibits the AXL receptor tyrosine kinase, a member of the TAM family of receptors. By binding to the extracellular IG1 domain of AXL, tilvestamab blocks its interaction with its ligand GAS6, thereby inhibiting downstream signaling pathways such as PI3K/AKT, MAPK/ERK, and STAT3. These pathways are implicated in tumor cell proliferation, migration, invasion, immune evasion, and therapeutic resistance. Overexpression of AXL is associated with poor prognosis in various cancers. Tilvestamab has demonstrated preclinical efficacy in inhibiting tumor growth and metastasis across multiple solid tumor models and is being investigated clinically for use in solid tumors (including non-small cell lung cancer), platinum-resistant high-grade serous ovarian cancer (HGSOC), acute myeloid leukemia (AML), and glioblastoma. The drug was developed by BerGenBio[1][2][3][5][7][8].

Other names

tilvestamab